Revolutionary Cancer Treatment Could Transform Lives by 2027

A groundbreaking cancer treatment known as CAR T-cell therapy, developed in Wellington, New Zealand, has shown the potential to provide long-term remission for patients facing terminal diagnoses. According to experts, this innovative therapy could be integrated into the public health system by 2027, contingent on essential approvals from health officials.

BioOra Limited, a biotechnology company partially owned by the Malaghan Institute of Medical Research, is preparing to mass-produce CAR T-cell therapy for both public and private healthcare systems upon the completion of ongoing clinical trials. This treatment option represents a lifeline for many patients who are currently financing their care abroad, particularly in countries like China.

Manufacturing Plans and Challenges Ahead

The company is establishing a sophisticated manufacturing facility in Christchurch, incorporating automated systems designed to produce therapies accurately and with minimal risk of contamination. John Robson, managing director of BioOra, expressed concerns about the pace at which the public system is responding. He emphasized that delays could endanger lives and hinder the company’s progress.

“We’re kind of on this knife edge of, will they go fast enough for us? … Quarter 1 of 2027 is a distinct possibility for public access, but it has to dovetail with a funding stream,” Robson stated. If public access is delayed, BioOra may offer the treatment privately, with discussions underway with interested healthcare providers.

CAR T-cell therapy works by extracting a patient’s immune cells, genetically modifying them to target and destroy cancer cells, and then reinfusing them into the patient’s bloodstream. This treatment has become a standard care option for certain blood cancers in countries like Australia but is not yet available in New Zealand’s public or private sectors.

The Malaghan Institute aims to change this, having developed its own CAR T formulation that has yielded promising results in phase 1 clinical trials. More than half of the lymphoma patients who had exhausted other treatment options experienced remission within months, and the therapy was associated with fewer severe side effects compared to existing commercial alternatives.

Future Prospects and Financial Implications

Phase 2 of the clinical trial is set to enroll its final patient with large B-cell lymphoma by October 2023, with results expected to support Medsafe approval. BioOra is currently producing the CAR T for the trial from its Wellington location but is raising tens of millions of dollars in private investment to construct its new facility in Christchurch.

The company plans to operate under good manufacturing practice (GMP) standards, which are crucial for ensuring the safety and efficacy of pharmaceutical products. Robson indicated that the facility is expected to be certified and operational by the end of 2026, coinciding with the conclusion of the trials. Initially, the facility aims to produce engineered cells for 160 patients in its first year, increasing capacity to over 300 in the second year.

Securing timely public access to this treatment hinges on obtaining special funding from the government, which could facilitate access until a more sustainable funding model is established through Health NZ. While Robson refrained from disclosing the per patient cost, he noted it would be significantly lower than the $1 million charged in markets like Australia and the United States, and comparable to the approximately $200,000 in China.

Robson highlighted the broader economic implications, suggesting that the upfront costs of CAR T-cell therapy could be offset by the long-term savings in healthcare expenses. “If you have a 20 or 30-year-old treated and they effectively go down this curative pathway, then their benefit and input to New Zealand is huge, because they carry on working and being productive,” he explained.

The Malaghan Institute recently launched a fundraising campaign to cover the $17 million cost of the phase 2 trial, which is separate from the funding efforts of BioOra. In the last fundraising round, the company secured $15 million from private investors and is now looking to raise between $30 million and $45 million.

BioOra’s ultimate vision is to establish New Zealand as a leader in immunotherapy, potentially attracting international patients seeking treatment. Robson asserted that producing therapies locally would not only reduce costs but also enhance New Zealand’s capacity to address various diseases over the next decade.

As BioOra navigates regulatory pathways, the company remains focused on leveraging its innovations to improve patient outcomes. The upcoming Medical Products Bill, set to be introduced later this year, aims to facilitate more flexible approval processes for treatments like CAR T-cell therapy, signaling a shift towards more accessible cancer care in New Zealand.